recurrent pericarditis
-
With an effective anti-inflammatory and anti-fibrotic agent, Cardiol Therapeutics is focused on our hearts
Trialing cannabidiol-based therapies for pericarditis and myocarditis while developing new therapies for heart failure — Cardiol is well-capitalized…
-
David Elsley of Cardiol Therapeutics talks about their global Phase II clinical trials for the treatment of heart diseases
In this InvestorIntel interview, Chris Thompson talks to Cardiol Therapeutics Inc.’s (NASDAQ: CRDL | TSX: CRDL) CEO, President and…
-
Cardiol Therapeutics is concerned with affairs of the heart
One thing I really enjoy about writing for InvestorIntel is all the random learning I get from reading…
